Global Research Output of Lutetium-177 PSMA in Prostate Cancer: Bibliometric and Altmetric Analyses

Abstract

Aim The integration of innovative radio-pharmaceutical agents targeting prostate-specific membrane antigen (PSMA) within nuclear medicine has transformed prostate cancer detection and management. This study aims to investigate the present landscape of [¹⁷⁷Lu]Lu-PSMA in prostate cancer, elucidating trends, global contributions, scholarly outlets, institutions, and thematic concentrations with an aim to inform forthcoming research endeavors.

Methods We systematically probed the Scopus repository for relevant [¹⁷⁷Lu]Lu-PSMA literature. An assessment of bibliometric and altmetric data was carried out. Finally, we assessed the correlation between the altmetric attention scores and the number of citations for the retrieved data.

Results Spanning January 2015 to July 2023, the study encompassed 466 articles concerning [¹⁷⁷Lu]Lu-PSMA therapy for prostate cancer. Predominant citation accolades gravitated towards metastatic castration-resistant prostate cancer investigations and assessments of [¹⁷⁷Lu]Lu-PSMA therapy’s safety and efficacy. Further research encompassed adverse effects linked to [¹⁷⁷Lu]Lu-PSMA intervention, including xerostomia, thrombocytopenia, anemia, and fatigue. Germany emerged as the primary academic contributor, with The Journal of Nuclear Medicine dominating publications (n = 55). A moderate significant correlation was detected between the number of citations and altmetric attention scores .

Conclusion The findings highlight the growing interest and advancements in the utilization of [¹⁷⁷Lu]Lu-PSMA therapy in prostate cancer and offer a comprehensive global perspective on future research directions.

Keywords

Prostate Cancer - [177Lu]Lu-PSMA - radiopharmaceuticals - nuclear medicine - Radionuclide Therapy - SPECT

Publication History

Received: 21 September 2023

Accepted after revision: 27 November 2023

Article published online:
23 January 2024

• References

• 1 Rawla P. Epidemiology of prostate cancer. World journal of oncology 2019; 10 (02) 63
• 2 Murray TB. The pathogenesis of prostate cancer. Exon Publications 2021; 29-41
• 3 Fendler WP, Eiber M, Beheshti M. et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. European journal of nuclear medicine and molecular imaging 2023; 50 (05) 1466-1486
• 4 Schwarzenboeck SM, Rauscher I, Bluemel C. et al. PSMA ligands for PET imaging of prostate cancer. Journal of Nuclear Medicine 2017; 58 (10) 1545-1552
• 5 Cerci JJ, Fanti S, Lobato EE. et al. Diagnostic performance and clinical impact of 68Ga-PSMA-11 PET/CT imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA Study). Journal of Nuclear Medicine 2022; 63 (02) 240-247
• 6 Al-Ibraheem A, Abuhijla F, Salah S. et al. The influence of 68Ga-prostate-specific membrane antigen PET/computed tomography on prostate cancer staging and planning of definitive radiation therapy. Nuclear Medicine Communications 2021; 42 (07) 811-817
• 7 Tsechelidis I, Vrachimis A. PSMA PET in imaging prostate cancer. Frontiers in Oncology 2022; 12: 831429
• 8 Hirmas N, Al-Ibraheem A, Herrmann K. et al. [68 Ga] PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer. Molecular imaging and biology 2019; 21: 574-581
• 9 Al-Ibraheem A, Mohamedkhair A. Current status of theranostics in Jordan. Nuclear Medicine and Molecular Imaging 2019; 53: 7-10
• 10 Sgouros G, Bodei L, McDevitt MR. et al. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nature reviews Drug discovery 2020; 19 (09) 589-608
• 11 Al-Ibraheem A, Sweedat D, Anwer F. et al. Efficacy and Safety of Lu-177 PSMA in Heavily Pretreated Population with mCRPC; Experience from King Hussein Cancer Center (KHCC) in Jordan. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING: SPRINGER ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES; 2021. p. S317.
• 12 Juzeniene A, Stenberg VY, Bruland ØS. et al. Preclinical and clinical status of PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer. Cancers 2021; 13 (04) 779
• 13 Al-Ibraheem A, Doudeen RM, Juaidi D. et al. 161Tb-PSMA Radioligand Therapy: First-in-human SPECT/CT Imaging. Journal of Nuclear Medicine 2023; 64 (08) 1322-1323
• 14 Al-Ibraheem A, Scott AM. 161Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer. Nuclear Medicine and Molecular Imaging 2023; 1-4
• 15 Yeung AWK, Goto TK, Leung WK. The changing landscape of neuroscience research, 2006–2015: a bibliometric study. Frontiers in neuroscience 2017; 11: 120
• 16 Sweileh WM, Wickramage K, Pottie K. et al. Bibliometric analysis of global migration health research in peer-reviewed literature (2000–2016). BMC public health 2018; 18 (01) 1-18
• 17 Kocyigit BF, Akyol A. Bibliometric and altmetric analyses of publication activity in the field of Behcet’s disease in 2010–2019. J Korean Med Sci 2021; 36 (32) e207
• 18 Ellegaard O, Wallin JA. The bibliometric analysis of scholarly production: How great is the impact?. Scientometrics 2015; 105: 1809-1831
• 19 Gasparyan AY, Yessirkepov M, Voronov AA. et al. Article-level metrics. Journal of Korean Medical Science 2021; 36 (11) e74
• 20 Zimba O, Gasparyan AY. Social media platforms: a primer for researchers. Reumatologia/Rheumatology 2021; 59 (02) 68-72
• 21 Zimba O, Radchenko O, Strilchuk L. Social media for research, education and practice in rheumatology. Rheumatology international 2020; 40 (02) 183-190
• 22 van den Hoven AF, Keijsers RG, Lam MG. et al. Current research topics in FAPI theranostics: a bibliometric analysis. European Journal of Nuclear Medicine and Molecular Imaging 2023; 50 (04) 1014-1027
• 23 Sartor O, De Bono J, Chi KN. et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. New England Journal of Medicine 2021; 385 (12) 1091-1103
• 24 Rahbar K, Ahmadzadehfar H, Kratochwil C. et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. Journal of Nuclear Medicine 2017; 58 (01) 85-90
• 25 Kratochwil C, Giesel FL, Stefanova M. et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. Journal of Nuclear Medicine 2016; 57 (08) 1170-1176
• 26 Gudenkauf LM, Chavez MN, Maconi ML. et al. Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer. Journal of Nuclear Medicine 2023; 64 (06) 869-872
• 27 Hennrich U, Eder M. [177Lu] Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals 2022; 15 (10) 1292
• 28 Weineisen M, Schottelius M, Simecek J. et al. 68Ga-and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. Journal of Nuclear Medicine 2015; 56 (08) 1169-1176
• 29 Ahmadzadehfar H, Rahbar K, Kürpig S. et al. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI research 2015; 5 (01) 1-8
• 30 Violet J, Jackson P, Ferdinandus J. et al. Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. Journal of Nuclear Medicine 2019; 60 (04) 517-523
• 31 Tatkovic A, McBean R, Wong D. Lu177-PSMA therapy for men with advanced prostate cancer: 18 months survival analysis in a single Australian tertiary institution. Journal of Medical Imaging and Radiation Oncology 2021; 65 (06) 740-747
• 32 Wang F, Li Z, Feng X. et al. Advances in PSMA-targeted therapy for prostate cancer. Prostate Cancer and Prostatic Diseases 2022; 25 (01) 11-26
• 33 Pathmanandavel S, Crumbaker M, Nguyen A. et al. The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN). Journal of Nuclear Medicine 2023; 64 (01) 69-74
• 34 Privé BM, Peters SM, Muselaers CH. et al. Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study. Clinical Cancer Research 2021; 27 (13) 3595-3601
• 35 Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Therapeutic Advances in Medical Oncology 2023; 1. DOI
• 36 Uijen M, Derks Y, Merkx R. et al. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. European journal of nuclear medicine and molecular imaging 2021; 48 (13) 4350-4368
• 37 AlRyalat SAS, Malkawi LW, Momani SM. Comparing bibliometric analysis using PubMed, Scopus, and Web of Science databases. JoVE (Journal of Visualized Experiments) 2019; 152: e58494